X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Panacea Biotech with Aurobindo Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PANACEA BIOTECH vs AUROBINDO PHARMA - Comparison Results

PANACEA BIOTECH    Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

AUROBINDO PHARMA 
   Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PANACEA BIOTECH AUROBINDO PHARMA PANACEA BIOTECH/
AUROBINDO PHARMA
 
P/E (TTM) x -16.1 20.8 - View Chart
P/BV x 1.9 3.9 48.7% View Chart
Dividend Yield % 0.0 0.3 -  

Financials

 PANACEA BIOTECH   AUROBINDO PHARMA
EQUITY SHARE DATA
    PANACEA BIOTECH
Mar-14
AUROBINDO PHARMA
Mar-18
PANACEA BIOTECH/
AUROBINDO PHARMA
5-Yr Chart
Click to enlarge
High Rs149809 18.4%   
Low Rs82504 16.3%   
Sales per share (Unadj.) Rs84.1281.1 29.9%  
Earnings per share (Unadj.) Rs-18.341.4 -44.3%  
Cash flow per share (Unadj.) Rs-6.750.9 -13.2%  
Dividends per share (Unadj.) Rs02.50 0.0%  
Dividend yield (eoy) %00.4 0.0%  
Book value per share (Unadj.) Rs83.7199.4 42.0%  
Shares outstanding (eoy) m61.25585.88 10.5%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.42.3 58.8%   
Avg P/E ratio x-6.315.9 -39.7%  
P/CF ratio (eoy) x-17.212.9 -133.6%  
Price / Book Value ratio x1.43.3 41.9%  
Dividend payout %06.0 0.0%   
Avg Mkt Cap Rs m7,074384,630 1.8%   
No. of employees `0002.817.3 15.9%   
Total wages/salary Rs m1,44921,308 6.8%   
Avg. sales/employee Rs Th1,874.19,500.7 19.7%   
Avg. wages/employee Rs Th527.01,229.4 42.9%   
Avg. net profit/employee Rs Th-407.71,397.9 -29.2%   
INCOME DATA
Net Sales Rs m5,154164,666 3.1%  
Other income Rs m1001,020 9.8%   
Total revenues Rs m5,254165,686 3.2%   
Gross profit Rs m-76637,718 -2.0%  
Depreciation Rs m7115,580 12.7%   
Interest Rs m1,503777 193.4%   
Profit before tax Rs m-2,88132,380 -8.9%   
Minority Interest Rs m1131 34.4%   
Prior Period Items Rs m-60-   
Extraordinary Inc (Exp) Rs m1,7710-   
Tax Rs m178,183 0.2%   
Profit after tax Rs m-1,12124,229 -4.6%  
Gross profit margin %-14.922.9 -64.9%  
Effective tax rate %-0.625.3 -2.3%   
Net profit margin %-21.814.7 -147.9%  
BALANCE SHEET DATA
Current assets Rs m3,810121,878 3.1%   
Current liabilities Rs m8,36586,806 9.6%   
Net working cap to sales %-88.421.3 -415.0%  
Current ratio x0.51.4 32.4%  
Inventory Days Days156130 119.9%  
Debtors Days Days6768 98.3%  
Net fixed assets Rs m14,48081,037 17.9%   
Share capital Rs m61586 10.5%   
"Free" reserves Rs m903116,218 0.8%   
Net worth Rs m5,127116,804 4.4%   
Long term debt Rs m5,8324,512 129.2%   
Total assets Rs m19,433211,052 9.2%  
Interest coverage x-0.942.7 -2.1%   
Debt to equity ratio x1.10 2,944.5%  
Sales to assets ratio x0.30.8 34.0%   
Return on assets %2.011.8 16.6%  
Return on equity %-21.920.7 -105.4%  
Return on capital %3.627.4 13.3%  
Exports to sales %24.50-   
Imports to sales %10.20-   
Exports (fob) Rs m1,264NA-   
Imports (cif) Rs m525NA-   
Fx inflow Rs m1,53980,727 1.9%   
Fx outflow Rs m94234,700 2.7%   
Net fx Rs m59746,027 1.3%   
CASH FLOW
From Operations Rs m59919,548 3.1%  
From Investments Rs m-438-19,570 2.2%  
From Financial Activity Rs m-3038,642 -3.5%  
Net Cashflow Rs m-1418,922 -1.6%  

Share Holding

Indian Promoters % 74.5 54.1 137.7%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.6 8.0 7.5%  
FIIs % 1.3 27.7 4.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 23.6 10.2 231.4%  
Shareholders   10,259 69,601 14.7%  
Pledged promoter(s) holding % 35.1 8.6 409.7%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PANACEA BIOTECH With:   SANOFI INDIA  ABBOTT INDIA  FRESENIUS KABI ONCO.  CIPLA  TORRENT PHARMA  

Compare PANACEA BIOTECH With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Brexit Deal; Key Q2FY19 Results & Top Stocks in Focus Today(Pre-Open)

On Thursday, Indian share markets ended marginally higher led by bank stocks and finance stocks. At the closing bell, the BSE Sensex ended up by 119 points.

Related Views on News

AUROBINDO PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 21.6% (Quarterly Result Update)

Nov 14, 2018 | Updated on Nov 14, 2018

For the quarter ended September 2018, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (down 21.6% YoY). Sales on the other hand came in at Rs 48 bn (up 7.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Oct 3, 2018 | Updated on Oct 3, 2018

Here's an analysis of the annual report of AUROBINDO PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of AUROBINDO PHARMA. Also includes updates on the valuation of AUROBINDO PHARMA.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)

Nov 9, 2018

All blue chip companies are large caps but all large caps are not blue chips.

Get this Small Cap Logistics Company at a 16% Discount Right Now...(Profit Hunter)

Nov 6, 2018

If you turn the clock back, the current macroeconomic climate is nothing new. The markets have seen them all, and every downcycle has been succeeded by gravity defying gains...more so in the small cap space. This time will be no different.

This Was a Large Cap. But Was It Safe?(Chart Of The Day)

Nov 9, 2018

Investing in large caps is not always safe. Consider the right metrics to judge the safety and quality of large caps.

Does it Make Sense to Invest in Offshore Funds?(Outside View)

Nov 6, 2018

Many investors prefer to invest in offshore funds because of the rupee depreciation and on-going downtrend in the markets, but it is to be invested only when there is no option available to invest in India.

Which Equity Mutual Funds to Buy Now?(Outside View)

Nov 13, 2018

PersonalFN explains that in falling markets investing in equity mutual funds can be beneficial in long run by choosing the right equity mutual fund scheme.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PANACEA BIOTECH SHARE PRICE


Nov 15, 2018 (Close)

TRACK PANACEA BIOTECH

  • Track your investment in PANACEA BIOTECH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PANACEA BIOTECH

PANACEA BIOTECH - PLETHICO PHARMA COMPARISON

COMPARE PANACEA BIOTECH WITH

MARKET STATS